Details

Autor(en) / Beteiligte

• Galiè, Nazzareno
• Barberà, Joan A
• Frost, Adaani E
• Ghofrani, Hossein-Ardeschir
• Hoeper, Marius M
• McLaughlin, Vallerie V
• Peacock, Andrew J
• Simonneau, Gérald
• Vachiery, Jean-Luc
• Grünig, Ekkehard
• Oudiz, Ronald J
• Vonk-Noordegraaf, Anton
• White, R. James
• Blair, Christiana
• Gillies, Hunter
• Miller, Karen L
• Harris, Julia H.N
• Langley, Jonathan
• Rubin, Lewis J

Titel

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension

Ist Teil von

• The New England journal of medicine, 2015-08, Vol.373 (9), p.834-844

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Patients with previously untreated pulmonary arterial hypertension who were randomly assigned to combination therapy with ambrisentan and tadalafil had a significantly lower risk of a composite clinical failure outcome at 20 months than did the pooled monotherapy group. Regardless of the initiating trigger, pulmonary arterial hypertension results in the altered synthesis of a variety of vasoactive substances derived from the endothelium. 1 Current therapies for pulmonary arterial hypertension 2 target abnormalities in one of three intracellular pathways with signaling dysfunction: the prostacyclin, nitric oxide, or endothelin pathway. 1 However, no single class of drug is consistently effective in treating all patients, which suggests that no single pathway plays a dominant pathogenic role. 3 , 4 Combination therapy with agents that target several different pathways may potentially increase the overall therapeutic effect on the mechanisms of this disease 5 and provide additional clinical benefits. 6 – . . .